Ovarian Cancer Clinical Trials (as of April 2018)

ENGOT-ov50/BGOG/INNOVATE-3

Leading group: BGOG

Clinical Trial Study: INNOVATE-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer (PROC)

Number of patients accrued: 0

Planned number of patients: 538

Participating groups:

TBA

Planned start in 4Q 2018 

 

ENGOT-ov49/MaNGO/RADAR

Leading group: MaNGO

Clinical Trial Study: A multicenter, open-label phase II trial of customized dosing (Rapid Adjustment of Dose to reduce Adverse Reactions “RADAR” dosing) of niraparib as maintenance therapy in platinum sensitive ovarian, fallopian tube or primary peritoneal recurrent cancer patients.

Number of patients accrued: 0

Planned number of patients: 105

Participating groups:

AGO, NCRI

Planned start in 4Q 2018 

 

 

ENGOT-ov48/BGOG/EUDARIO

Leading group: BGOG

Clinical Trial Study: European trial on enhanced DNA repair Inhibion in ovarian cancer (EUDARIO).

Number of patients accrued: 0

Planned number of patients: 120

Participating groups:

A-AGO, GINECO, MITO, NOGGO

Planned start in June 2018

 

 

ENGOT-ov47-TR /NOGGO-AGO TR2 

Leading group: NOGGO

Clinical Trial Study: Prospective study of HE4 serum level in patients with first platinum sensitive relapsed ovarian cancer.

Number of patients accrued: 0

Planned number of patients: 500

Participating groups:

A-AGO, AGO, BGOG, GEICO, MaNGO, MITO, NCRI

Planned start in May 2018

 

 

ENGOT-ov46/AGO/DUO-O

Leading group: AGO

Clinical Trial Study: A phase III randomised, double-blind, placebo-controlled, multicentre study of Durvalumab (MEDI4736) in combination with chemotherapy and Bevacizumab, followed by maintenance Durvalumab, Bevacizumab and Olaparib in newly diagnosed advanced ovarian cancer patients (DUO-O)

Number of patients accrued: 0

Planned number of patients: 927

Participating groups:

TBA

Planned start in 2Q 2018

 

 

ENGOT-ov45/NCRI/ATHENA

Leading group: NCRI

Clinical Trial Study: ATHENA: A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Nivolumab and Rucaparib combination switch maintenance following front-line platinum-based chemotherapy in ovarian cancer patients 

Number of patients accrued: 0

Planned number of patients: 1000

Participating groups:

AGO, Cancer Trials Ireland, DGOG, GEICO, MITO, NOGGO, PGOG, SGCTG

Planned start in March 2018

 

ENGOT-ov44/GINECO/FIRST trial

Leading group: GINECO

Clinical Trial Study: A randomized phase III comparing platinum and TSR-042 (PD-L1 inhibitor) followed by Niraparib and TSR-042 maintenance therapy versus  adaptive standard platinum-based treatment in patients with stage III or IV cancer of the ovary, fallopian tube or peritoneum

Number of patients accrued: 0

Planned number of patients: 700

Participating groups:

AGO, BGOG, CEEGOG, DGOG, GEICO, HeCOG, ISGO, MITO, NCRI, NSGO

Planned start in 3Q 2018

 

 

ENGOT-ov43/BGOG

Leading group: BGOG

Clinical Trial Study: Randomized phase III first line study in ovarian cancer comparing paclitaxel carboplatinum, with paclitaxel/carboplatin and pembrolizumab and olaparib

Number of patients accrued: 0

Planned number of patients: 1500

Participating groups:

TBA

Planned start in 2Q 2018

 

 

ENGOT-ov42/NSGO/AVANOVA-Immune1

Leading group: NSGO

Clinical Trial Study: A randomized phase II trial to explore efficacy of Immune checkpoint inhibitor TSR042 in relapsed ovarian cancer

Number of patients accrued: 0

Planned number of patients: 223

Participating groups:

BGOG, CEEGOG, DGOG, GEICO, GINECO, ISGO, MaNGO, NCRI, NOGGO, PGOG, SGCTG, TRSGO

Planned start in 3Q 2018

 

 

ENGOT-ov41/GEICO/ANITA

Leading group: GEICO

Clinical Trial Study: ANITA (Atezolizumab and NIraparib Treatment Association in recurrent ovarian cancer): A randomized phase III trial of platinum-based chemotherapy followed by niraparib maintenance with or without atezolizumab in patients

Number of patients accrued: 0

Planned number of patients: 414

Participating groups:

TBA

 

 

ENGOT-ov40/NOGGO S13/Expression VI

Leading group: NOGGO

Clinical Trial Study: Caroline meets HANNA – Holistic analysis of longterm survivors with ovarian cancer

Number of patients accrued: 227

Planned number of patients: 600

Participating groups:

A-AGO, BGOG, CEEGOG, GEICO, MITO, TRSGO, (Romania, PASGO)

 

 

ENGOT-ov39/MITO/IMaGYN 050

Leading group: MITO

Clinical Trial Study: A phase III, multicenter, randomized, study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed Stage III or Stage IV ovarian, fallopian tube, or primary peritoneal cancer

Number of patients accrued: 468

Planned number of patients: 1300

Participating groups:

A-AGO, AGO, BGOG, MaNGO, NSGO, CEEGOG, GEICO, GINECO, HeCOG, PGOG, TRSGO, ISGO

 

 

ENGOT-ov38/GINECO/OReO

Leading group: GINECO

Clinical Trial Study: Double blind phase IIIb study: Olaparib Retreatment in late recurrent Ovarian cancer

Number of patients accrued: 23

Planned number of patients: 416

Participating groups:

AGO, BGOG, GEICO, ISGO, MITO, NSGO, SGCTG, MaNGO, NCRI, PGOG

 

 

ENGOT-ov37/GEICO/CERULEAN

Leading group: GEICO

Clinical Trial Study: CERULEAN: A randomized, double-blind phase III trial of CRLX101 + weekly paclitaxel versus CRLX101 vehicle + weekly paclitaxel in patients with platinum-resistant ovarian cancer

Number of patients accrued: TBA

Planned number of patients: 320

Participating groups: TBA

 

  

ENGOT-ov36/SGCTG – NSGO

Leading group: SGCTG

Clinical Trial Study: A phase II trial of a triple angiokinase inhibitor (BIBF1120) in the treatment of patients with recurrent clear cell ovarian cancer

Number of patients accrued: 57

Planned number of patients: 120

Participating groups:

EORTC, GINECO, NCRI, NSGO

 

 

ENGOT-ov35/NCRI/ICON 9

Leading group: NCRI

Clinical Trial Study: An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy

Number of patients accrued: 0

Planned number of patients: 618

Participating groups:

EORTC, GEICO, MaNGO, MITO, (ANZGOG, NCIC)

  

 

ENGOT-ov34/AGO Ovar 2.29

Leading group: AGO

Clinical Trial Study: Atezolizumab in combination with Bevacizumab +/- Chemotherapy versus Chemo-BEV standard in recurrent ovarian cancer – a randomised trial

Number of patients accrued: 664

Planned number of patients: 777

Participating groups: 

A-AGO, BGOG, GEICO, GINECO, NSGO, SAKK

 

 

ENGOT-ov33/AGO Ovar OP.7/TRUST

Leading group: AGO

Clinical Trial Study:

TRUST: Trial on Radical Upfront Surgical Therapy

Number of patients accrued: 346

Planned number of patients: 686

Participating groups:

GINECO, MaNGO, MITO, NOGGO

 

 

ENGOT-ov32/MITO 23

Leading group: MITO

Clinical Trial Study: Randomized phase III trial on Trabectedin (ET 743) vs clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype patients

Number of patients accrued: 106

Planned number of patients: 244

Participating groups:

MaNGO, GEICO

 

  

ENGOT-ov30/NSGO/UMB1

Leading group: NSGO

Clinical Trial Study: Umbrella Trial in Recurrent Ovarian Cancer

Number of patients accrued: 0

Planned number of patients: 25

Participating groups:

BGOG, EORTC, NOGGO, SGCTG, (ANZGOG, COGI, GOTIC, PMHC)

 

 

ENGOT-ov29/GINECO/ATALANTE

Leading group: GINECO

Clinical Trial Study: Randomized trial comparing atezolizumab versus placebo in patients with 1st or 2nd platinum-sensitive relapse of OC treated with carboplatin combination + bevacizumab

Number of patients accrued: 271

Planned number of patients: 405

Participating groups:

A-AGO, AGO, BGOG, CEECOG, GEICO, ISGO

 

 

ENGOT-ov27/BGOG-ov18/MORAB003-011

Leading group: BGOG

Clinical Trial Study: A Randomized, double-blind, placebo-controlled, phase 2 study to assess the efficacy and safety of Farletuzumab (MORAb 003) in combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in subjects with low CA125 platinum-sensitive ovarian cancer

Number of patients accrued: 186

Planned number of patients: 210

Participating groups:

GEICO, MITO, NOGGO

 

 

ENGOT-ov26/GEICO/1509 - PRIMA study

Leading group: GEICO

Clinical Trial Study: A phase 3, randomized, double-blind, placebo-controlled, multicenter study of Niraparib maintenance treatment in patients with advanced ovarian cancer following response on front-line platinum-based chemotherapy

Number of patients accrued: 468

Planned number of patients: 530

Participating groups:

AGO, BGOG, Cancer Trials Ireland, GINECO, ISGO, MITO, NSGO

 

 

ENGOT-ov25/GINECO/PAOLA

Leading group: GINECO

Clinical Trial Study: Phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab

Number of patients accrued: 806

Planned number of patients: 786

Participating groups:

A-AGO, AGO, BGOG, GEICO MaNGO, MITO, NSGO, (GOTIC)

 

 

ENGOT-ov24/NSGO/AVANOVA

Leading group: NSGO

Clinical Trial Study: Niraparib and/or Niraparib-bevacizumab combination against bevacizumab alone in women with platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer

Number of patients accrued: 98

Planned number of patients: 94

Participating groups:

GEICO, ISGO, MITO

 

 

ENGOT-ov23/GINECO/EWOC-1

Leading group: GINECO

Clinical Trial Study: Multicenter, randomized trial of carboplatin +/-paclitaxel in vulnerable elderly patients with stage IIB- IV advanced ovarian cancer

Number of patients accrued: 120

Planned number of patients: 240

Participating groups: MITO, NSGO

 

 

ENGOT-ov20/AGO-OVAR OP.4/Desktop 3

Leading group: AGO

Clinical Trial Study: Randomised trial investigating secondary debulking versus no-secondary debulking in platin sensitive disease

Number of patients accrued: 129

Final number of patients: 244 

Participating groups:

A-AGO, BGOG, GEICO, GINECO, MaNGO, MITO, NSGO, (CRCTU UK, KGOG, SGOG)

 

  

ENGOT-ov18/AGO-OVAR 2.21

Leading group: AGO

Clinical Trial Study: A prospective randomized phase III trial of carboplatin/gemcitabine/bevacizumab vs. carboplatin/pegylated liposomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer

Final number of patients: 682

Participating groups:

A-AGO, GINECO, SGCTG, (ANZGOG)

 

 

ENGOT-ov15/AGO-OVAR 17

Leading group: AGO

Clinical Trial Study: A prospective randomised phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian, fallopian tube or peritoneal cancer. The BOOST (Bevacizumab Ovarian Optiam Standard Treatment) trial 

Final number of patients: 927

Participating Groups:

GINECO, NSGO

 

 

ENGOT-ov 13/NCRI/ICON8B

Leading group: NCRI

Clinical Trial Study: A phase III randomised trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to standard three weekly chemotherapy and bevacizumab for the first-line treatment of women with newly diagnosed high-risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer

Number of patients accrued: 660

Planned number of patients: 660

Participating groups:

Cancer Trials Ireland, (CTU EOC)

 

 

ENGOT-ov 13/NCRI/ICON8

Leading group: NCRI

Clinical Trial Study: An international phase III randomised trial of dose fractionated chemotherapy compared to standard three weekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer

Final number of patients: 1566

Participating groups:

Cancer Trials Ireland, (ANZGOG, GICOM, KGOG)